Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110721 · ClinicalTrials.gov registry record · Phase 2
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Galectin Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00110721: Clinical Trial Phase 2 study, sponsored by Galectin Therapeutics.
NCT00110721 is a Phase 2 study that was terminated before completion, run by Galectin Therapeutics. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110721, a Phase 2 study, was terminated before completion, sponsored by Galectin Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles for at least 2 cycles or until their disease progresses.
Primary Outcome
Tumor response as characterized by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Interventions
- DRUG GM-CT-01 plus 5-Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Why NCT00110721 stopped before completion
NCT00110721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which GM-CT-01 plus 5-Fluorouracil is the first listed.
NCT00110721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00110721 about?
NCT00110721 is a clinical study titled "GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer". This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with appr...
What is the current status of trial NCT00110721?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00110721?
The interventions under investigation include: GM-CT-01 plus 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00110721?
This trial is sponsored by Galectin Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00110721's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia